Group 1 - The report outlines the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", which sets a roadmap for the future development of the traditional Chinese medicine (TCM) industry, emphasizing the promotion of national medicines and famous products [3][12][13] - The core goal by 2030 is to establish a collaborative system across the entire industry chain, enhance the supply of raw materials, and significantly improve the levels of digitalization and greening [3][13] - Specific quantitative targets include cultivating 60 high-standard raw material bases, establishing 5 innovation centers, and constructing 20 smart factories and 10 green factories [3][13][14] Group 2 - The market size for TCM products is projected to reach approximately 506.1 billion yuan in 2025, with the market for TCM raw materials expected to grow to 220.6 billion yuan [21][24][26] - The planting area for TCM materials is estimated to be around 57 million mu in 2025, indicating a steady growth trend [20][22] - The production of traditional Chinese medicine is expected to decline, with an estimated output of 1.855 million tons in 2025, down from 1.953 million tons in 2024 [28][32] Group 3 - The report identifies five companies related to the TCM industry chain listed on the Beijing Stock Exchange: Zizhong Palace, Datang Pharmaceutical, Oukan Pharmaceutical, New Ganjing, and Biological Valley [29][30] - Among the companies, Jiren Pharmaceutical is highlighted with a projected revenue of 1.23 billion yuan and a net profit of approximately 131.84 million yuan for 2024 [51] - The report notes that 52.38% of the pharmaceutical and biological stocks on the exchange experienced price increases, with TCM stocks showing a weekly increase of 4.29% [4][42]
北交所策略专题报告：中药五年新蓝图发布，掘金北证民族药与名品推广双主线